In alignment with the tumor-infiltrating CD8+ T cell data, we saw no difference between the “exhausted” (untreated mean 16.00%, nivo treated mean 19.32%) CD8+ T cells after nivolumab treatment (Fig. 1C,D). This evidence concerns the gene CD8A and neoplasm.